SILVER SPRING
Saphnelo Pen cleared for SLE self-administration
- Sponsor
- AstraZeneca $AZN
- Drug
- Saphnelo · anifrolumab
- Indication
- systemic lupus erythematosus
FDA approved AstraZeneca's Saphnelo Pen autoinjector for once-weekly subcutaneous self-administration in adult SLE patients.
What this means
Saphnelo is an antibody treatment for lupus that works by blocking certain immune system proteins called interferons, which can drive inflammation. Today FDA cleared a new pen device that lets patients give themselves weekly Saphnelo injections at home instead of needing clinic visits. This change could make treatment more convenient for people with lupus, potentially helping them stick to their medication schedule better.
Drug Watch — recent news on Saphnelo
- Subcutaneous Anifrolumab Improves Disease Activity in Moderate-to-Severe Systemic Lupus Erythematosus: Results from the Phase 3 TULIP-SC Trial - Vera Health
- Anifrolumab Shows Real-World Promise in Systemic Lupus Erythematosus - European Medical Journal
- Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - Yahoo! Finance Canada
- Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace
- Study finds Anifrolumab may help restore overall immune health in people with systemic lupus erythematosus - Lupus Foundation of America
Sponsor Watch — recent news on AstraZeneca
- Cathie Wood Just Bet Big on This Biotech Stock
- Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?
- The First Oral Cholesterol Pill Is Here. Which of These 5 Stocks Benefits Most?
- MSD wins FDA approval for cholesterol pill to help plug Keytruda void
- Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill